Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Alaunos Therapeutics ( (TCRT) ) is now available.
On July 3, 2025, Alaunos Therapeutics, Inc. held its Annual Meeting of Stockholders where several key proposals were voted on. The stockholders elected three directors to serve until the 2026 Annual Meeting and approved the selection of Cherry Bekaert LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. Additionally, they approved an advisory vote on executive compensation, a reverse stock split, an increase in authorized common stock, and an amendment to the 2020 Equity Incentive Plan. The meeting concluded with the approval to adjourn if necessary for further proxy solicitation.
Spark’s Take on TCRT Stock
According to Spark, TipRanks’ AI Analyst, TCRT is a Neutral.
Alaunos Therapeutics’ overall score is primarily impacted by its weak financial performance with ongoing losses and negative cash flows. While the technical analysis shows some positive momentum, the negative P/E ratio and lack of dividends underscore valuation challenges. The absence of earnings call and corporate events information further limits the stock’s appeal.
To see Spark’s full report on TCRT stock, click here.
More about Alaunos Therapeutics
Average Trading Volume: 34,354
Technical Sentiment Signal: Sell
Current Market Cap: $10.03M
Learn more about TCRT stock on TipRanks’ Stock Analysis page.